Headlines about Amyris (NASDAQ:AMRS) have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amyris earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 86 out of 100, meaning that recent news coverage is very likely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
- Amyris Inc (AMRS) Announces Next Step in Developing Industrial Biotechnology Hub in Southeast Asia – Smarter Analyst (smarteranalyst.com)
- Amyris Partners with Queensland on Biofutures Acceleration Program in Next Step Toward Planned Development of Biorefinery (finance.yahoo.com)
- FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Amyris, Inc. (AMRS) & Lead Plaintiff Deadline – June 19, 2017 (finance.yahoo.com)
- DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against Amyris, Inc. and Reminds Investors with Losses to Contact the Firm (finance.yahoo.com)
- DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Amyris, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2017 – AMRS (feeds.benzinga.com)
Shares of Amyris (AMRS) opened at 2.77 on Thursday. The firm’s 50-day moving average price is $4.38 and its 200 day moving average price is $7.76. The company’s market cap is $54.86 million. Amyris has a 12 month low of $2.67 and a 12 month high of $18.15.
Amyris (NASDAQ:AMRS) last announced its earnings results on Monday, May 15th. The biotechnology company reported ($1.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by $0.60. The business had revenue of $13 million during the quarter, compared to the consensus estimate of $32.30 million. The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.55) earnings per share. Equities research analysts anticipate that Amyris will post ($4.01) earnings per share for the current fiscal year.
Several brokerages recently issued reports on AMRS. Zacks Investment Research raised Amyris from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 16th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Amyris in a research note on Tuesday, May 23rd. Finally, ValuEngine cut Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $31.13.
COPYRIGHT VIOLATION NOTICE: This story was reported by Mideast Time and is owned by of Mideast Time. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.mideasttime.com/amyris-amrs-given-daily-coverage-optimism-score-of-0-24/1801857.html.
In other Amyris news, major shareholder (Mauritius) Pte Ltd Maxwell sold 129,059 shares of the business’s stock in a transaction on Monday, March 27th. The shares were sold at an average price of $0.48, for a total value of $61,948.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Patrick Y. Yang purchased 300,000 shares of the company’s stock in a transaction on Friday, May 19th. The stock was acquired at an average price of $0.29 per share, with a total value of $87,000.00. Following the purchase, the director now owns 153,000 shares of the company’s stock, valued at $44,370. The disclosure for this purchase can be found here. In the last three months, insiders sold 3,021,027 shares of company stock worth $1,792,123. 11.30% of the stock is owned by corporate insiders.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.